An Australian backed and enabled “smart” orthopaedic knee implant set to revolutionise knee replacements has been given marketing authorisation by the US Food and Drug Administration.
The canturioTMte device has been backed by Melbourne-based healthcare investment firm,
BioScience Managers (BSM) to assist with the aggregation of patient data for software developed by
Melbourne-based healthcare informatics company Summatix.
CanturioTMte will track data including step count and walking speed; the data collection is passive and the device does not rely on daily patient compliance to capture the information.
The “smart” orthopaedic implant will stream this data to the cloud for analysis to support Physician
monitoring of the patient’s mobility and recovery.
Managing Partner of BSM, Jeremy Curnock Cook, said the authorisation to market the canturioTMte
device in the US was a game-changer for the Australian-backed device.
“The FDA marketing authorisation of the canturioTMte device opens the way for sales of this ground breaking device in the world’s biggest orthopaedic market,” Mr Curnock Cook said.
Senior Partner of BSM, Dr Amanda Gillon, said the device used data analytics to help improve the
remote monitoring and visibility of the patients mobility through recovery and the continuum of care.
“Patient data is becoming increasingly valuable as it is now used as an additional, objective,
measurement tool to help monitor with the goal to improve clinical outcomes via data analytics, and
inform reimbursement decisions by government and private health insurers,” Dr Gillon said.
“While the approval process was lengthy, the FDA actively supported the process along the way with the benefits afforded to designated Breakthrough medical device.
“It wasn’t a ‘me too’ application, it was a whole new area the FDA knew would become more
important as time goes on,” Dr Gillon said.
Under collaboration between Canary Medical and NYSE-listed Zimmer Biomet, canturioTMte is
combined with Zimmer Biomet’s proven and trusted Persona® The Personalized Knee® and
marketed under the brand Persona IQ®.
Canary develops sensor-based implants that enable remote patient monitoring to help improve
recovery rates and streamline clinical workflow. Canary is eyeing a broader pipeline of similar devices for applications including hips, shoulders, hands, trauma and coronary stents.
Canary recently moved to full ownership of Summatix by acquiring BSM’s 45 per cent stake.
The equity deal means BSM is now Canary’s second biggest preference shareholder, holding
approximately 7.5 per cent of the combined company. Canary’s acquisition of Summatix creates a
global leader in the emerging medical SaaS and data analytics sector.